Neurocrine Biosciences (NASDAQ: NBIX) — Perfil da empresa, notícias e dados financeiros
Neurocrine Biosciences is a biotech firm dedicated to treatments for neurologic, psychiatric, and endocrine disorders.
Neurocrine Biosciences
Neurocrine Biosciences is a biopharmaceutical company focused on discovering, developing, and commercializing targeted treatments for patients with neurological, endocrine, and psychiatric disorders. Headquartered in San Diego, California, the company develops therapies for conditions with significant unmet medical needs. Its commercial portfolio includes FDA-approved therapeutics targeting movement disorders, congenital adrenal hyperplasia, and other complex health conditions. Neurocrine Biosciences operates clinical-stage research and development pipelines spanning neurology, neuroendocrinology, and neuropsychiatry, collaborating with strategic industry partners to advance novel small molecule therapeutics and biologic drug candidates toward commercial availability.
Resumo
Operações
Produtos e/ou serviços de Neurocrine Biosciences
- VMAT2 Inhibitors: Small molecule vesicular monoamine transporter 2 therapeutics designed to treat adults with tardive dyskinesia and chorea associated with Huntington's disease, representing the primary commercial product line and revenue driver.
- CRF1 Receptor Antagonists: Oral selective corticotropin-releasing factor type 1 receptor antagonists designed for the treatment of classic congenital adrenal hyperplasia in adult and pediatric patients, supporting commercial expansion in neuroendocrinology.
- COMT Inhibitors: Once-daily catechol-O-methyltransferase inhibitor adjunct therapies administered alongside levodopa and carbidopa for adult patients with Parkinson's disease experiencing motor fluctuations and end-of-dose off episodes, enhancing therapeutic control.
- GnRH Receptor Antagonists: Licensed small molecule gonadotropin-releasing hormone receptor antagonist therapies commercialized through strategic industry partnerships for the management of endometriosis and uterine fibroids in adult female patient populations.
- Clinical Neurology Pipeline: Research and development programs evaluating targeted small molecule candidates for neurological conditions, including clinical-stage selective sodium channel inhibitors designed for focal onset seizures, essential tremor, and related disorders.
- Neuropsychiatry Pipeline: Clinical-stage development programs focused on psychiatric conditions, evaluating novel selective muscarinic receptor agonists and targeted therapeutic candidates for schizophrenia, major depressive disorder, and mood disorders.
equipe executiva do Neurocrine Biosciences
- Kyle W. GanoPresident, CEO & Director
- Matthew C. AbernethyChief Financial Officer
- Jude OnyiaChief Scientific Officer
- Eric S. BenevichChief Commercial Officer
- Eiry Wyn RobertsChief Medical Officer
- Wylie W. ValeCo-Founder
- Lawrence SteinmanCo-Founder of Neurocrine
- Aaron VosburghSenior Vice President of Finance & Accounting
- Lewis ChoiChief Information Officer
- Todd TushlaVice President of Investor Relations
Últimas notícias sobre a Neurocrine Biosciences
Neurocrine reports positive 2-year pediatric CAH data
United StatesNeurocrine reports positive data for INGREZZA in patients with IDD and tardive dyskinesia
United StatesNeurocrine Biosciences enters obesity race with novel CRF2 peptide agonist
United StatesNeurocrine Biosciences to acquire Soleno in $2.9B rare disease expansion
United StatesNeurocrine advances next-gen VMAT2 candidate for tardive dyskinesia
United StatesNeurocrine reports superior Ingrezza PET imaging data
United States
Principais indicadores financeiros
Resultados divulgados pela Neurocrine Biosciences, em USD.
- Cap. de mercado
- 14,8 bi
- Receita (TTM)
- 3,4 bi
- P/L
- 21.4
- LPA (diluído, TTM)
- 6.8
- Dividend yield
- —
- Margem de lucro
- 20.9%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 2,9 bi | 619,1 mi | 478,6 mi | |
| 2,4 bi | 570,5 mi | 341,3 mi | |
| 1,9 bi | 250,9 mi | 249,7 mi | |
| 1,5 bi | 249 mi | 154,5 mi |